Literature DB >> 11403222

Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination.

H C von Büdingen1, N Tanuma, P Villoslada, J C Ouallet, S L Hauser, C P Genain.   

Abstract

Myelin/oligodendrocyte glycoprotein (MOG) is a surface-exposed antigen of myelin and an important target for autoimmune responses which mediate inflammatory demyelination in the central nervous system. Experimentally, MOG induces strong pathogenic T cell responses in many strains of laboratory animals. Immunological studies in humans also identify MOG as a surprisingly prevalent antigenic molecule among the myelin proteins. In addition, the encephalitogenic properties of MOG are linked to the induction of antibody responses which have been demonstrated to directly promote central nervous system demyelination, a hallmark neuropathological feature in disorders such as human multiple sclerosis. Factors responsible for autoimmunity to MOG likely include genetic influences as well as other mechanisms, which are the subject of intense investigation. This article reviews experimental data currently available on specificity and pathogenic roles of T cell and antibody responses against MOG, which have implications relevant to multiple sclerosis and related disorders.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11403222     DOI: 10.1023/a:1011031014433

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  102 in total

1.  Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2',3'-cyclic nucleotide 3'-phosphodiesterase in the CNS of adult rats.

Authors:  C Brunner; H Lassmann; T V Waehneldt; J M Matthieu; C Linington
Journal:  J Neurochem       Date:  1989-01       Impact factor: 5.372

2.  Induction of EAE in mice with recombinant human MOG, and treatment of EAE with a MOG peptide.

Authors:  B Devaux; F Enderlin; B Wallner; D E Smilek
Journal:  J Neuroimmunol       Date:  1997-05       Impact factor: 3.478

3.  Myelin oligodendrocyte glycoprotein induces experimental autoimmune encephalomyelitis in the "resistant" Brown Norway rat: disease susceptibility is determined by MHC and MHC-linked effects on the B cell response.

Authors:  A Stefferl; U Brehm; M Storch; D Lambracht-Washington; C Bourquin; K Wonigeit; H Lassmann; C Linington
Journal:  J Immunol       Date:  1999-07-01       Impact factor: 5.422

Review 4.  Glycoproteins of myelin sheaths.

Authors:  R H Quarles
Journal:  J Mol Neurosci       Date:  1997-02       Impact factor: 3.444

5.  Structure of the human myelin/oligodendrocyte glycoprotein gene and multiple alternative spliced isoforms.

Authors:  D Pham-Dinh; B Della Gaspera; N Kerlero de Rosbo; A Dautigny
Journal:  Genomics       Date:  1995-09-20       Impact factor: 5.736

6.  B-cell-deficient mice develop experimental allergic encephalomyelitis with demyelination after myelin oligodendrocyte glycoprotein sensitization.

Authors:  P Hjelmström; A E Juedes; J Fjell; N H Ruddle
Journal:  J Immunol       Date:  1998-11-01       Impact factor: 5.422

7.  Studies on autoimmune encephalomyelitis in the guinea pig. II. An in vitro investigation on the nature, properties, and specificity of the serum-demyelinating factor.

Authors:  R Lebar; J M Boutry; C Vincent; R Robineaux; G A Voisin
Journal:  J Immunol       Date:  1976-05       Impact factor: 5.422

8.  Human myelin/oligodendrocyte glycoprotein: a new member of the L2/HNK-1 family.

Authors:  D Burger; A J Steck; C C Bernard; N Kerlero de Rosbo
Journal:  J Neurochem       Date:  1993-11       Impact factor: 5.372

9.  Antibodies to myelin/oligodendrocyte-specific protein and myelin/oligodendrocyte glycoprotein signal distinct changes in the organization of cultured oligodendroglial membrane sheets.

Authors:  C A Dyer; J M Matthieu
Journal:  J Neurochem       Date:  1994-02       Impact factor: 5.372

10.  The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat.

Authors:  M Adelmann; J Wood; I Benzel; P Fiori; H Lassmann; J M Matthieu; M V Gardinier; K Dornmair; C Linington
Journal:  J Neuroimmunol       Date:  1995-12       Impact factor: 3.478

View more
  24 in total

Review 1.  Management of secondary-progressive multiple sclerosis.

Authors:  Gavin Giovannoni
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

2.  Substrain differences reveal novel disease-modifying gene candidates that alter the clinical course of a rodent model of multiple sclerosis.

Authors:  Leslie E Summers deLuca; Natalia B Pikor; Jennifer O'Leary; Georgina Galicia-Rosas; Lesley A Ward; Dustin Defreitas; Trisha M Finlay; Shalina S Ousman; Lucy R Osborne; Jennifer L Gommerman
Journal:  J Immunol       Date:  2010-02-19       Impact factor: 5.422

Review 3.  Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury.

Authors:  Dustin J Donnelly; Phillip G Popovich
Journal:  Exp Neurol       Date:  2007-06-30       Impact factor: 5.330

4.  Active immunization using a single dose immunotherapeutic abates established EAE via IL-10 and regulatory T cells.

Authors:  Agnieszka Rynda-Apple; Eduardo Huarte; Massimo Maddaloni; Gayle Callis; Jerod A Skyberg; David W Pascual
Journal:  Eur J Immunol       Date:  2010-12-29       Impact factor: 5.532

5.  Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis.

Authors:  Dun Zhou; Rajneesh Srivastava; Stefan Nessler; Verena Grummel; Norbert Sommer; Wolfgang Brück; Hans-Peter Hartung; Christine Stadelmann; Bernhard Hemmer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-01       Impact factor: 11.205

6.  Elevated intrathecal myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis.

Authors:  Eric C Klawiter; Laura Piccio; Jeri-Anne Lyons; Robert Mikesell; Kevin C O'Connor; Anne H Cross
Journal:  Arch Neurol       Date:  2010-09

7.  KIR2DL4-HLAG interaction at human NK cell-oligodendrocyte interfaces regulates IFN-γ-mediated effects.

Authors:  P P Banerjee; L Pang; S S Soldan; S M Miah; A Eisenberg; S Maru; A Waldman; E A Smith; Y Rosenberg-Hasson; D Hirschberg; A Smith; D V Ablashi; K S Campbell; J S Orange
Journal:  Mol Immunol       Date:  2018-11-24       Impact factor: 4.407

8.  B cells as a target of immune modulation.

Authors:  Kathleen Hawker
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

9.  Myelin/oligodendrocyte glycoprotein-deficient (MOG-deficient) mice reveal lack of immune tolerance to MOG in wild-type mice.

Authors:  Cécile Delarasse; Philippe Daubas; Lennart T Mars; Csaba Vizler; Tobias Litzenburger; Antonio Iglesias; Jan Bauer; Bruno Della Gaspera; Anna Schubart; Laurence Decker; Dalia Dimitri; Guy Roussel; Andrée Dierich; Sandra Amor; Andre Dautigny; Roland Liblau; Danielle Pham-Dinh
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

10.  Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis.

Authors:  Patrice H Lalive; Til Menge; Cecile Delarasse; Bruno Della Gaspera; Danielle Pham-Dinh; Pablo Villoslada; H-C von Büdingen; Claude P Genain
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.